Editing Lung cancer (section)

==Prognosis==
[[File:SEER Lung cancer 5-year survival 2022.pdf|thumb|upright=1.5|alt=Graph showing five-year survival from lung cancer increasing from 1975 (11.7% of people) to 2015 (25.2%).|Percent of people who survive five years from a lung cancer diagnosis over time, according to the [[Surveillance, Epidemiology, and End Results|NIH SEER]] program]]

{| class="wikitable floatright" style="text-align:center;font-size:90%;width:25%;margin-left:1em"
|+ style="background:#E5AFAA;"|Five-year survival in those diagnosed with lung cancer, by stage{{sfn|Goldstraw|Chansky|Crowley|Rami-Porta|2016|loc="Figure 2"}}
|- style="background: #E5AFAA;text-align:center;font-size:90%;"
! abbr="Type" | Clinical stage
!Five-year survival (%)
|-
| IA1
| 92
|-
|IA2
|83
|-
|IA3
|77
|-
| IB
| 68
|-
| IIA
| 60
|-
| IIB
| 53
|-
| IIIA
| 36
|-
| IIIB
| 26
|-
|IIIC
|13
|-
| IVA
| 10
|-
|IVB
|0
|}

Around 19% of people diagnosed with lung cancer survive [[Five-year survival rate|five years from diagnosis]], though prognosis varies based on the stage of the disease at diagnosis and the type of lung cancer.{{sfn|Rivera|Mody|Weiner|2022|loc="Introduction"}} Prognosis is better for people with lung cancer diagnosed at an earlier stage; those diagnosed at the earliest TNM stage, IA1 (small tumor, no spread), have a two-year survival of 97% and five-year survival of 92%.{{sfn|Goldstraw|Chansky|Crowley|Rami-Porta|2016|loc="Figure 2"}} Those diagnosed at the most-advanced stage, IVB, have a two-year survival of 10% and a five-year survival of 0%.{{sfn|Goldstraw|Chansky|Crowley|Rami-Porta|2016|loc="Figure 2"}} Five-year survival is higher in women (22%) than men (16%).{{sfn|Rivera|Mody|Weiner|2022|loc="Introduction"}} Women tend to be diagnosed with less-advanced disease, and have better outcomes than men diagnosed at the same stage.{{sfn|Rivera|Mody|Weiner|2022|loc="Prognostic and Predictive Factors in Lung Cancer"}} Average five-year survival also varies across the world, with particularly high five-year survival in Japan (33%), and five-year survival above 20% in 12 other countries: Mauritius, Canada, the US, China, South Korea, Taiwan, Israel, Latvia, Iceland, Sweden, Austria, and Switzerland.{{sfn|Allemani|Matsuda|Di Carlo|Harewood|2018|loc="Lung"}}

SCLC is particularly aggressive. 10–15% of people survive five years after a SCLC diagnosis.{{sfn|Horn|Iams|2022|loc="Treatment – Small-Cell Lung Cancer"}} As with other types of lung cancer, the extent of disease at diagnosis also influences prognosis. The average person diagnosed with limited-stage SCLC survives 12–20 months from diagnosis; with extensive-stage SCLC around 12 months.{{sfn|Horn|Iams|2022|loc="Treatment – Small-Cell Lung Cancer"}} While SCLC often responds initially to treatment, most people eventually relapse with chemotherapy-resistant cancer, surviving an average 3–4 months from the time of relapse.{{sfn|Horn|Iams|2022|loc="Treatment – Small-Cell Lung Cancer"}} Those with limited stage SCLC that go into complete remission after chemotherapy and radiotherapy have a 50% chance of brain metastases developing within the next two years – a chance reduced by prophylactic cranial irradiation.{{sfn|Rivera|Mody|Weiner|2022|loc="Treatment of Small Cell Lung Cancer"}}

Several other personal and disease factors are associated with improved outcomes. Those diagnosed at a younger age tend to have better outcomes. Those who smoke or experience weight loss as a symptom tend to have worse outcomes. Tumor mutations in [[KRAS]] are associated with reduced survival.{{sfn|Rivera|Mody|Weiner|2022|loc="Prognostic and Predictive Factors in Lung Cancer"}}

===Experience===
The uncertainty of lung cancer prognosis often causes stress, and makes future planning difficult, for those with lung cancer and their families.{{sfn|Temel|Petrillo|Greer|2022|loc="Coping with Prognostic Uncertainty"}} Those whose cancer goes into remission often experience fear of their cancer returning or progressing, associated with poor quality of life, negative mood, and functional impairment. This fear is exacerbated by frequent or prolonged surveillance imaging, and other reminders of cancer risks.{{sfn|Temel|Petrillo|Greer|2022|loc="Coping with Prognostic Uncertainty"}}